Sparsentan is a dual-acting angiotensin II receptor blocker (ARB) and endothelin type A (ETA) receptor antagonist approved for the treatment of primary immunoglobulin A nephropathy (IgAN) in adults at risk of disease progression. By targeting two key pathways involved in renal injury, Sparsentan helps reduce proteinuria and slow kidney function decline.
It is administered orally and offers a novel therapeutic approach to proteinuric kidney diseases, particularly where existing monotherapies are insufficient.
Indications include:
∙ IgA nephropathy (IgAN)
∙ Under investigation for focal segmental glomerulosclerosis (FSGS) and other glomerular diseases
Parent: Sparsentan
Parent: Sparsentan
Sparsentan is synthesized via multi-step organic synthesis, involving specific modifications to achieve its dual-receptor blocking activity. Given its chronic oral use, impurity levels must meet ICH Q3A/B guidelines and regulatory standards from the FDA and EMA.
Process-Related Impurities
Degradation Impurities
Elemental Impurities
Analytical Techniques for Impurity Detection
Sparsentan is used to treat IgA nephropathy (IgAN) in adults at risk of progression. It helps lower proteinuria, which is a key marker of disease severity.
It blocks both angiotensin II receptors and endothelin A receptors, reducing intraglomerular pressure, inflammation, and fibrosis in the kidneys.
Sparsentan already affects the RAAS pathway. Caution is needed if used with ACE inhibitors, ARBs, or potassium-sparing diuretics due to risk of hyperkalemia and renal dysfunction.
Store at room temperature, protected from light and moisture. Follow storage instructions on the product label.
